BrainsWay is an industry leader in the field of transcranial magnetic stimulation (TMS). BrainsWayâs flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions. BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US. The company also has approval in Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications. BrainsWay has an experienced business and development management team, as well as the backing of key scientific opinion leaders. BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY. Source
No articles found.
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical compan...
Spero Therapeutics, Inc. is a multi-asset, clin...
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing...
Ovid Therapeutics is a biopharmaceutical compan...
HealthEquity provides a solution to an issue of growing importance to American fam...
HealthEquity provides a solution to an issue of...
Apyx⢠Medical Corporation (formerly known as BovieŽ Medical Corporation) is an ...
Apyx⢠Medical Corporation (formerly known as ...
Trinity Biotech specializes in the development, manufacture and marketing of diagn...
Trinity Biotech specializes in the development,...
Tandem Diabetes Care, Inc. is a medical device company dedicated to improving the ...
Tandem Diabetes Care, Inc. is a medical device ...
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focuse...
Royal Philips (NYSE: PHG, AEX: PHIA) is a leadi...
Join the National Investor Network and get the latest information with your interests in mind.